Evan Lipson, MD, on Nivolumab Plus Relatlimab for Advanced Melanoma
Source: Med Page Today, July 2022
New data further validate nivolumab plus relatlimab as an effective treatment option for patients with advanced melanoma and support the benefit of dual checkpoint blockade, researchers said.
Previously, RELATIVITY-047, a global, randomized, double-blind, phase II/III study, had met its primary endpoint of progression-free survival (PFS) after 13.2 months of follow-up. Relatlimab, a human LAG-3 blocking antibody, and nivolumab, an anti-PD-1 agent, as a fixed-dose combination demonstrated a significant PFS benefit, with a median PFS of 10.1 months with the combination versus 4.6 months with nivolumab monotherapy, with a manageable safety profile.